GlassScriptPhysician profile
Ross M Ramsey
NPI 1770712986
$5,283.95
in general payments reported to CMS, 2019-2025
32 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $865 · 2021: $900 · 2022: $939 · 2023: $793 · 2024: $671 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $943.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $635.81 | 2019-2025 | |
| Lilly USA, LLC | $500.31 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.20 | 2019-2024 | Jardiance |
| Mylan Specialty L.P. | $342.39 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $338.14 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $314.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $281.97 | 2019-2023 | Breztri |
| Pfizer INC. | $240.65 | 2019-2022 | |
| Amgen INC. | $227.13 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $135.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $111.21 | 2020-2023 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $94.11 | 2020-2021 | |
| Amarin Pharma, INC. | $82.48 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $73.76 | 2022-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $72.43 | 2024 | 1788 |
| Kowa Pharmaceuticals America, INC. | $64.62 | 2019-2021 | |
| Allergan, INC. | $57.22 | 2020 | |
| Horizon Therapeutics Plc | $56.10 | 2019-2022 | |
| Viatris Specialty LLC | $50.63 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $39.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.32 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.31 | 2021 | |
| Currax Pharmaceuticals LLC | $27.11 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $25.34 | 2019 | |
| Inspire Medical Systems, INC. | $19.75 | 2024 | Inspire |
| Dexcom, INC. | $18.58 | 2022 | |
| Radius Health, INC. | $14.94 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.91 | 2023 | Inpefa |
| Exact Sciences Corporation | $14.69 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $13.33 | 2024 | Austedo Xr |
| Nalpropion Pharmaceuticals LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.